Publications

Publications

Select publications regarding antisense technology and TTR amyloidosis

April 12, 2012
Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy
Ackermann et al. Amyloid

July 15, 2011
Rate of Progression of Transthyretin Amyloidosis
Benson et al. American Journal of Cardiology

January 18, 2006
Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides
Benson et al. Muscle & Nerve

ApoC-III (volanesorsen, FCS and FPL)

August 5,  2018
Evaluating the impact of peer support and connection on the quality of life of patients with familial chylomicronemia syndrome
Salvatore et al. Expert Opinion on Orphan Drugs

June 11,  2018
The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS Study
Arca et al. Expert Review of Cardiovascular Therapy

May 22,  2018
Characterizing Familial Chylomicronemia Syndrome: Baseline Data of the APPROACH Study
Blom et al. Journal of Clinical Lipidology 

April 22,  2018
Familial chylomicronemia syndrome: Bringing to life dietary recommendations throughout the life span
Williams et al. Journal of Clinical Lipidology                                                                                                                      *Independent publication funded by Akcea Therapeutics                                                     

April 18,  2018
The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study
Davidson et al. Journal of Clinical Lipidology 

March 30,  2018
Clinical and biochemical features of different molecular etiologies of familial chylomicronemia
Hegele et al. Journal of Clinical Lipidology

March 12, 2018
Inhibition of Apolipoprotein C-III with GalNAc-Conjugated Antisense Drug Potently Lowers Fasting Serum Apolipoprotein C-III and Triglyceride Levels in Healthy Volunteers with Elevated Triglycerides
Alexander et al. (Poster presentation) American College of Cardiology Annual Scientific Session & Expo.

September 11,  2017
The burden of familial chylomicronemia syndrome from the patients’ perspective
Gelrud et al. Expert Review of Cardiovascular Therapy

March 24, 2017
The burden of familial chylomicronemia syndrome: interim results from the IN-FOCUS study
Davidson et al. Expert Review of Cardiovascular Therapy

November 8, 2016
Building a better understanding of the burden of disease in familial chylomicronemia syndrome
Ahmad et al. Expert Review of Clinical Pharmacology

August 27, 2016
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes
Digenio et al. Diabetes Care

August 12, 2015
Shutting down the messenger: Antisense treatment for hypertriglyceridemia
Wang, Andrew Z. Science Translational Medicine

July 30, 2015
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet et al. The New England Journal of Medicine

December 4, 2014
Targeting APOC3 in the Familial Chylomicronemia Syndrome
Gaudet et al. The New England Journal of Medicine

High Lipoprotein [LP(a)]

November 2, 2017
Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials 
Marcovina et al. Journal of Clinical Lipidology

September 21, 2016
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Viney et al. The Lancet

September 15, 2015
Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis
Capoulade et al. The Journal of the American College of Cardiology

July 22, 2015
Antisense therapy targeting apolipoprotein(a): a randomized, double-blind, placebo-controlled phase 1 study
Tsimikas et al. The Lancet

Angiopoietin-like 3 [ANGPTL3]

July 20, 2017
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Graham et al. The New England Journal of Medicine

June 14, 2017
Dyslipidaemia: ANGPTL3: a therapeutic target for atherosclerosis
Lim. Nature Reviews Cardiology